Adding Liraglutide to High Dose Insulin: Breaking the Cycle

NCT01505673 · Completed

Last updated 2026-05-28

This clinical trial is testing whether adding the medication liraglutide to high-dose insulin therapy improves blood sugar control in adults with type 2 diabetes and obesity.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 71 people

Who can join Ages 18+ · all sexes

Timeline Started 2012-01 · est. completion 2016-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01505673 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a high-dose insulin regimen (\>1.8 units/kg/day) in patients with uncontrolled (HbA1c \>7.5%) type 2 diabetes mellitus will improve blood sugar control. It also evaluates the effect of liraglutide on liver and pancreatic fat content, explores the mechanism of blood sugar improvement by assessing weight and pancreatic hormone release, and assesses blood pressure, lipid profile, and liver function. Finally it will look at patient quality of life and safety.

Treatments tested

Liraglutide also known as Victoza Drug

Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
Saline Drug

Placebo injection of 1.8mg saline once daily for 6-months

Main thing measured	Glycemic Control Measured by HbA1c
Sponsor	Ildiko Lingvay
Conditions studied	Type 2 Diabetes Mellitus, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01505673 ↗